Diagnos (TSE:ADK) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Diagnos Inc., a Canadian AI tech firm specializing in early health issue detection, announced the granting of 1,550,000 stock options to its directors and officers. These options will vest over two years, starting from their grant date on October 3, 2024, and have an exercise price of $0.37 per common share with an expiry on October 3, 2029.
For further insights into TSE:ADK stock, check out TipRanks’ Stock Analysis page.